1
|
Cetintepe T, Ozkan G, Kucukzeybek BP, Cetintepe L, Unal DK, Solmaz S, Aygun K, Acar AG, Bener S, Çallı AO, Payzın KB. Prognostic significance of bone marrow fibrosis in diffuse large B-cell lymphoma. Int J Lab Hematol 2024; 46:523-530. [PMID: 38361314 DOI: 10.1111/ijlh.14249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Accepted: 02/01/2024] [Indexed: 02/17/2024]
Abstract
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas. The aim of this study is to determine the relationship between the increase in the degree of fibrosis in the bone marrow and prognosis and mortality in newly diagnosed DLBCL. METHODS Bone marrow biopsy of 153 newly diagnosed DLBCL patients was determined by staining with reticulin, Masson's trichrome histochemical stain, and the degree of fibrosis was determined. RESULTS In the bone marrow biopsy performed at the time of diagnosis, bone marrow fibrosis (BMF) was observed in 70 patients. While BMF-1 was detected in 42 patients (60%), BMF-2 was detected in 25 patients (35%) and BMF-3 was detected in 3 patients (4%). As the degree of BMF increased, the median overall survival and median progression-free survival times were significantly shorter (p: 0.008), (p < 0.001). In patients with an increased degree of BMF, a significant decrease in leukocyte and neutrophil counts was observed after chemotherapy (p: 0.004). According to the results of the multivariate Cox regression model, it was determined that high NCCN-IPI risk (HR: 8.25; %95 CI: 1.09-62.52; p = 0.041) and being BMF ≥ 2 (HR: 3.75; %95 CI: 1.65-8.51; p = 0.002), increased the risk of death (p = 0.002, -2 loglikelihood = 392,553). CONCLUSION When the literature was reviewed, it was seen that this study was the first to define that bone marrow fibrosis grade 2 and above in DLBCL is a prognostic marker associated with worse survival. In the bone marrow pathology, which is examined to detect advanced disease in DLBCL, besides lymphomatous involvement, the detection of fibrosis grade is very important.
Collapse
Affiliation(s)
- Tugba Cetintepe
- Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Gamze Ozkan
- Department of Internal Medicine, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Betul Polat Kucukzeybek
- Department of Pathology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Lutfi Cetintepe
- Department of Nephrology, Karaburun State Hospital, Izmir, Turkey
| | - Demet Kiper Unal
- Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Serife Solmaz
- Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Kemal Aygun
- Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Alev Garip Acar
- Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Sadi Bener
- Department of Pathology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Aylin Orgen Çallı
- Department of Pathology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Kadriye Bahriye Payzın
- Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| |
Collapse
|
2
|
Geduk A, Oztas B, Eryılmaz BH, Demirsoy ET, Menguc MU, Unal S, Mersin S, Polat MG, Aygun K, Yenihayat EM, Albayrak H, Erol HA, Balcı S, Mehtap O, Tarkun P, Hacihanefioglu A. Correction to: Efects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma. Indian J Hematol Blood Transfus 2023; 39:518. [PMID: 37304480 PMCID: PMC10247911 DOI: 10.1007/s12288-023-01626-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
[This corrects the article DOI: 10.1007/s12288-022-01574-6.].
Collapse
Affiliation(s)
- Ayfer Geduk
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Berrin Oztas
- Department of Biochemistry, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Baldan Huri Eryılmaz
- Department of İnternal Medicine, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Esra Terzi Demirsoy
- Department of Hematology, Derince Training and Research Hospital, Health Sciences University, Kocaeli, Turkey
| | - Meral U. Menguc
- Department of Hematology, Medical Faculty, Bolu Abant İzzet Baysal University, Bolu, Turkey
| | - Serkan Unal
- Department of Hematology, Kastamonu Training and Research Hospital, Kastamonu, Turkey
| | - Sinan Mersin
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Merve Gokcen Polat
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Kemal Aygun
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Emel Merve Yenihayat
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Hayrunnisa Albayrak
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Hasim Atakan Erol
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Sibel Balcı
- Department of Biostatistics and Medical Informatics, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Ozgur Mehtap
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Pinar Tarkun
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| | - Abdullah Hacihanefioglu
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 UmuttepeKocaeli, Turkey
| |
Collapse
|
3
|
Geduk¹ A, Oztas B, Eryılmaz BH, Demirsoy ET, Menguc MU, Unal S, Mersin S, Polat MG, Aygun K, Yenihayat EM, Albayrak H, Erol HA, Balcı S, Mehtap¹ O, Tarkun¹ P, Hacihanefioglu¹ A. Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma. Indian J Hematol Blood Transfus 2023; 39:220-227. [PMID: 37006982 PMCID: PMC10064350 DOI: 10.1007/s12288-022-01574-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 08/31/2022] [Indexed: 11/07/2022] Open
Abstract
Purpose The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of serum advanced glycation end products (AGEs), soluble RAGE (sRAGE) and high mobility group box 1 (HMGB1), in multiple myeloma (MM). Methods AGEs, sRAGE and HMGB1 concentrations of 54 newly diagnosed MM patients and 30 healthy volunteers were measured by ELISA. The estimations were done only once at diagnosis. The medical records of the patients were evaluated. Results There was no significant difference between the AGEs and sRAGE levels between the patient and control groups (p = 0.273, p = 0.313). In ROC analysis, a HMGB1 cutoff value of > 9170 pg/ml accurately discriminated MM patients (AUC = 0.672, 95% CI 0.561-0.77, p = 0.0034). AGEs level was found to be significantly higher in early-stage disease and HMGB1 in advanced disease (p = 0.022, p = 0.026). High HMGB1 levels were detected in patients whose with better first-line treatment response (p = 0.019). At 36 months, 54% of patients with low AGE were alive, compared to 79% of patients with high AGE (p = 0.055). Patients with high HMGB1 levels tended to have a longer PFS (median 43 mo [95% CI; 20.68-65.31] ) compared to patients with low HMGB1 levels (median 25 mo [95% CI; 12.39-37.6], p = 0.054). Conclusion In this study, a significant elevation of serum HMGB1 level was found in MM patients. In addition, the positive effects of RAGE ligands on treatment response and prognosis were determined.
Collapse
Affiliation(s)
- Ayfer Geduk¹
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Berrin Oztas
- Department of Biochemistry, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Baldan Huri Eryılmaz
- Department of İnternal Medicine, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Esra Terzi Demirsoy
- Department of Hematology, Derince Training and Research Hospital, Health Sciences University, Kocaeli, Turkey
| | - Meral U. Menguc
- Department of Hematology, Medical Faculty, Bolu Abant İzzet Baysal University, Bolu, Turkey
| | - Serkan Unal
- Department of Hematology, Kastamonu Training and Research Hospital, Kastamonu, Turkey
| | - Sinan Mersin
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Merve Gokcen Polat
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Kemal Aygun
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Emel Merve Yenihayat
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Hayrunnisa Albayrak
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Hasim Atakan Erol
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Sibel Balcı
- Department of Biostatistics and Medical Informatics, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | - Ozgur Mehtap¹
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Pinar Tarkun¹
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| | - Abdullah Hacihanefioglu¹
- Department of Hematology, Medical Faculty, Kocaeli University, 11.km, 41380 Umuttepe, Kocaeli, Turkey
| |
Collapse
|